Literature DB >> 21737782

Rho-associated kinase activity, endothelial function, and cardiovascular risk factors.

Junko Soga1, Kensuke Noma, Takaki Hata, Takayuki Hidaka, Yuichi Fujii, Naomi Idei, Noritaka Fujimura, Shinsuke Mikami, Tatsuya Maruhashi, Yasuki Kihara, Kazuaki Chayama, Hitoshi Kato, James K Liao, Yukihito Higashi.   

Abstract

OBJECTIVE: Cardiovascular diseases are associated with chronic activation of Rho-associated kinases (ROCKs) and endothelial dysfunction. Both increased ROCK activity and endothelial dysfunction are thought to be closely associated with conventional cardiovascular risk factors. The purpose of this study was to determine the relationships between ROCK activity, endothelial function, and cardiovascular risk factors. METHODS AND
RESULTS: We evaluated ROCK activity in peripheral leukocytes by Western blot analysis and flow-mediated vasodilation by ultrasonography in 242 men who had no cardiovascular or cerebrovascular diseases (mean age, 40±10 years; range, 20 to 73 years). ROCK activity was defined as the ratio of phospho myosin-binding subunit on myosin light chain phosphatase to total myosin-binding subunit. Univariate regression analysis revealed that leukocyte ROCK activity significantly correlated with body mass index (r=0.29, P=0.003); systolic blood pressure (r=0.25, P=0.01); low-density lipoprotein cholesterol level (r=0.21, P=0.04); and Framingham risk factor score, a cumulative cardiovascular risk index for heart attack (r=0.31, P<0.001), and that flow-mediated vasodilation significantly correlated with age (r=-0.23, P=0.02), body mass index (r=0.19, P=0.05), systolic blood pressure (r=-0.22, P=0.03), total cholesterol level (r=-0.21, P=0.04), low-density lipoprotein cholesterol level (r=-0.22, P=0.04), glucose level (r=-0.20, P=0.04), and Framingham risk factor score (r=-0.37, P<0.001). There was a significant correlation between leukocyte ROCK activity and flow-mediated vasodilation (r=-0.41, P<0.001). Multivariate analysis revealed that flow-mediated vasodilation was an independent predictor of leukocyte ROCK activity.
CONCLUSIONS: These findings suggest that cumulative cardiovascular risk may enhance ROCK activity and endothelial dysfunction, leading to progression of cardiovascular diseases and outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737782      PMCID: PMC3852695          DOI: 10.1161/ATVBAHA.111.227892

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  Endothelium and control of vascular function. State of the Art lecture.

Authors:  P M Vanhoutte
Journal:  Hypertension       Date:  1989-06       Impact factor: 10.190

3.  Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.

Authors:  Chu Kataoka; Kensuke Egashira; Shujiro Inoue; Masao Takemoto; Weihua Ni; Masamichi Koyanagi; Shiro Kitamoto; Makoto Usui; Kozo Kaibuchi; Hiroaki Shimokawa; Akira Takeshita
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Effect of exercise on coronary endothelial function in patients with coronary artery disease.

Authors:  R Hambrecht; A Wolf; S Gielen; A Linke; J Hofer; S Erbs; N Schoene; G Schuler
Journal:  N Engl J Med       Date:  2000-02-17       Impact factor: 91.245

5.  Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.

Authors:  Akihiro Masumoto; Masahiro Mohri; Hiroaki Shimokawa; Lemmy Urakami; Makoto Usui; Akira Takeshita
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

6.  Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.

Authors:  P Verdecchia; C Porcellati; G Reboldi; R Gattobigio; C Borgioni; T A Pearson; G Ambrosio
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

7.  Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers.

Authors:  Takayuki Hidaka; Takaki Hata; Junko Soga; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Yasuki Kihara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertens Res       Date:  2010-02-05       Impact factor: 3.872

8.  Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.

Authors:  Sebastian Wolfrum; Andreas Dendorfer; Yoshiyuki Rikitake; Timothy J Stalker; Yulan Gong; Rosario Scalia; Peter Dominiak; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-19       Impact factor: 8.311

9.  Coronary risk prediction in adults (the Framingham Heart Study)

Authors:  P W Wilson; W P Castelli; W B Kannel
Journal:  Am J Cardiol       Date:  1987-05-29       Impact factor: 2.778

10.  Endothelial function and oxidative stress in renovascular hypertension.

Authors:  Yukihito Higashi; Shota Sasaki; Keigo Nakagawa; Hideo Matsuura; Tetsuya Oshima; Kazuaki Chayama
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

View more
  27 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

2.  Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.

Authors:  Takeshi Matsumoto; Kenji Oki; Masato Kajikawa; Ayumu Nakashima; Tatsuya Maruhashi; Yumiko Iwamoto; Akimichi Iwamoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Nobuoki Kohno; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

3.  Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial.

Authors:  Tatsuya Maruhashi; Kensuke Noma; Noritaka Fujimura; Masato Kajikawa; Takeshi Matsumoto; Takayuki Hidaka; Ayumu Nakashima; Yasuki Kihara; James K Liao; Yukihito Higashi
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

4.  Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.

Authors:  Shinji Kishimoto; Kenji Oki; Tatsuya Maruhashi; Masato Kajikawa; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Farina Mohamad Yusoff; Ayumu Nakashima; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

5.  Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.

Authors:  Francesca Schinzari; Manfredi Tesauro; Valentina Rovella; Nicola Di Daniele; Paolo Gentileschi; Nadia Mores; Umberto Campia; Carmine Cardillo
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-24       Impact factor: 4.310

6.  CKD Stimulates Muscle Protein Loss Via Rho-associated Protein Kinase 1 Activation.

Authors:  Hui Peng; Jin Cao; Rizhen Yu; Farhad Danesh; Yanlin Wang; William E Mitch; Jing Xu; Zhaoyong Hu
Journal:  J Am Soc Nephrol       Date:  2015-06-08       Impact factor: 10.121

7.  Sucrose Nonfermenting-Related Kinase Enzyme-Mediated Rho-Associated Kinase Signaling is Responsible for Cardiac Function.

Authors:  Stephanie M Cossette; Vijesh J Bhute; Xiaoping Bao; Leanne M Harmann; Mark A Horswill; Indranil Sinha; Adam Gastonguay; Shabnam Pooya; Michelle Bordas; Suresh N Kumar; Shama P Mirza; Sean P Palecek; Jennifer L Strande; Ramani Ramchandran
Journal:  Circ Cardiovasc Genet       Date:  2016-10-25

Review 8.  Annual reports on hypertension research 2020.

Authors:  Masaki Mogi; Yukihito Higashi; Kanako Bokuda; Atsuhiro Ichihara; Daisuke Nagata; Atsushi Tanaka; Koichi Node; Yoichi Nozato; Koichi Yamamoto; Ken Sugimoto; Hirotaka Shibata; Satoshi Hoshide; Hitoshi Nishizawa; Kazuomi Kario
Journal:  Hypertens Res       Date:  2021-10-15       Impact factor: 3.872

9.  Reduction in blood pressure improves impaired nitroglycerine-induced vasodilation in patients with essential hypertension.

Authors:  Tatsuya Maruhashi; Ayumu Nakashima; Shinji Kishimoto; Akimichi Iwamoto; Masato Kajikawa; Nozomu Oda; Yasuki Kihara; Yoshiki Aibara; Kensuke Noma; Yukihito Higashi
Journal:  Hypertens Res       Date:  2015-09-03       Impact factor: 3.872

10.  Rho-associated kinase activity is a predictor of cardiovascular outcomes.

Authors:  Masato Kajikawa; Kensuke Noma; Tatsuya Maruhashi; Shinsuke Mikami; Yumiko Iwamoto; Akimichi Iwamoto; Takeshi Matsumoto; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Ayumu Nakashima; Chikara Goto; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2013-12-30       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.